Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide–Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes
暂无分享,去创建一个
J. Holst | R. Pratley | C. Deacon | D. Gupta | O. Sideleva | D. Elahi | W. G. Tharp
[1] Andrea Mari,et al. A Model-Based Method for Assessing Insulin Sensitivity From the Oral Glucose Tolerance Test , 2001 .
[2] C. Mcintosh,et al. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. , 2009, Human molecular genetics.
[3] J. Holst,et al. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. , 2004, American journal of physiology. Endocrinology and metabolism.
[4] T. Kieffer,et al. Targeting the glucagon receptor family for diabetes and obesity therapy. , 2012, Pharmacology & therapeutics.
[5] Tanya Hansotia,et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. , 2007, The Journal of clinical investigation.
[6] H. Hauner,et al. Primary culture of human adipocyte precursor cells: expansion and differentiation. , 2012, Methods in molecular biology.
[7] T. Vilsbøll,et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes , 2009, Diabetologia.
[8] C. Mcintosh,et al. Glucose-dependent Insulinotropic Polypeptide (GIP) Stimulation of Pancreatic β-Cell Survival Is Dependent upon Phosphatidylinositol 3-Kinase (PI3K)/Protein Kinase B (PKB) Signaling, Inactivation of the Forkhead Transcription Factor Foxo1, and Down-regulation of bax Expression* , 2005, Journal of Biological Chemistry.
[9] R. Pederson,et al. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. , 2001, Diabetes.
[10] J. Leahy,et al. Physiologic and Pharmacologic Modulation of Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Expression in β-Cells by Peroxisome Proliferator–Activated Receptor (PPAR)-γ Signaling , 2010, Diabetes.
[11] Peter J Moate,et al. MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. , 2003, Diabetes technology & therapeutics.
[12] J. Holst,et al. Incretins, insulin secretion and Type 2 diabetes mellitus , 2004, Diabetologia.
[13] J. Holst,et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. , 2001, The Journal of clinical endocrinology and metabolism.
[14] J. Holst,et al. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. , 1998, Diabetes.
[15] J. Holst,et al. Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response. , 2017, American journal of physiology. Endocrinology and metabolism.
[16] R. Gimeno,et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial , 2018, The Lancet.
[17] F. Tinahones,et al. Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance. , 2014, The Journal of clinical endocrinology and metabolism.
[18] B. Spiegelman,et al. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.
[19] 任艳,et al. 胰岛素增敏剂一Thiazolidinediones研究现状 , 2000 .
[20] J. Holst,et al. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. , 2011, American journal of physiology. Endocrinology and metabolism.
[21] J. Holst,et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.
[22] S. Del Prato,et al. Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors , 2017, Diabetes, obesity & metabolism.
[23] Robert R. Henry,et al. Prevention of Diabetes With Pioglitazone in ACT NOW , 2013, Diabetes.
[24] S. Bonner-Weir,et al. Downregulation of GLP-1 and GIP Receptor Expression by Hyperglycemia , 2007, Diabetes.
[25] C. Mcintosh,et al. Adipocyte expression of the glucose-dependent insulinotropic polypeptide receptor involves gene regulation by PPARγ and histone acetylation , 2011, Journal of Lipid Research.
[26] M. Tschöp,et al. Reappraisal of GIP Pharmacology for Metabolic Diseases. , 2016, Trends in molecular medicine.
[27] R N Bergman,et al. Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. , 1990, The Journal of clinical endocrinology and metabolism.
[28] H. Hendrickson. Prevention of what? , 1983, Journal of the American Optometric Association.
[29] R. Hovorka,et al. ISEC: a program to calculate insulin secretion. , 1996, Computer methods and programs in biomedicine.
[30] D. Taura,et al. Inhibition of Gastric Inhibitory Polypeptide Receptor Signaling in Adipose Tissue Reduces Insulin Resistance and Hepatic Steatosis in High-Fat Diet–Fed Mice , 2017, Diabetes.
[31] M. Lazar,et al. Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. , 2005, Genes & development.
[32] A. Pfeiffer,et al. GIP receptor mRNA expression in different fat tissue depots in postmenopausal non-diabetic women , 2007, Regulatory Peptides.
[33] D. Drucker,et al. Pharmacology, physiology, and mechanisms of incretin hormone action. , 2013, Cell metabolism.
[34] J. Holst,et al. Transgenic Rescue of Adipocyte Glucose-dependent Insulinotropic Polypeptide Receptor Expression Restores High Fat Diet-induced Body Weight Gain* , 2011, The Journal of Biological Chemistry.
[35] Devjit Tripathy,et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. , 2011, The New England journal of medicine.
[36] J. Holst,et al. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects , 2003, Regulatory Peptides.
[37] C. Mcintosh,et al. Activation of Lipoprotein Lipase by Glucose-dependent Insulinotropic Polypeptide in Adipocytes , 2007, Journal of Biological Chemistry.
[38] C. Mcintosh,et al. Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). , 2009, Vitamins and hormones.
[39] Yuichiro Yamada,et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity , 2002, Nature Medicine.
[40] J. Holst,et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. , 2001, Diabetes.
[41] L. Groop,et al. Link Between GIP and Osteopontin in Adipose Tissue and Insulin Resistance , 2013, Diabetes.
[42] Bin Yang,et al. Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans , 2013, Science Translational Medicine.
[43] V. Fonseca. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. , 2003, The American journal of medicine.
[44] C. Mcintosh,et al. GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene , 2010, Journal of Lipid Research.
[45] E. Mazzaferri,et al. Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man. , 1975, The Journal of clinical endocrinology and metabolism.
[46] J. Holst,et al. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients , 2002, Diabetologia.